Source : Frost & Sullivan 
Tuesday, December 19, 2006 3:58PM IST (10:28AM GMT)
 
Advancements in Insulin Delivery Poised to Revolutionise Diabetes Management
Mumbai, Maharashtra, India

Innovative, non-invasive methods to deliver insulin are poised to transform diabetes management. Despite concerns about their safety and efficacy, an eager diabetic community is expected to support research into novel technologies that promote greater compliance and therefore improved disease management. Accordingly, the revenue potential across Europe of non-invasive insulin, particularly inhaled insulin, will be considerable.

Frost & Sullivan (http://www.pharma.frost.com) finds that the European Inhaled Insulin Market will earn revenues of $49.3 million in 2006 and estimates this to reach $611.7 million in 2012.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the Diabetes Drug Delivery Methods-Market and Technologies (B934-52) then send an e-mail to Shwetha Thomas, Corporate Communications, at sthomas@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

"Compliance is currently a major drawback in current diabetes delivery devices, with several patients suffering from Type 2 diabetes irregularly following or, in some cases, even discontinuing their insulin therapy due to pain or fear of injections," says Frost & Sullivan Research Analyst Sylvia Miriyam Findlay. "Through more convenient drug delivery methods, pharmaceutical companies, regulatory bodies and other government institutions can introduce better diabetes care and reduce costs related to diabetic complications caused by poor compliance."

At present, several methods of non-invasive insulin delivery, including oral, transdermal, nanotechnology-based and gene therapy-based ones, are under research. Efforts are also on to develop a diabetes vaccine. One of the most promising modes of delivery under investigation is that of inhaled insulin.

Leading participants in the diabetes medication market are vying to develop this new form of insulin delivery. Already, Exubera (Pfizer and Netkar) has become the first inhaled insulin to enter the market, while Novo Nordisk is pursuing final clinical studies on AerX with plans to launch it by 2008.

However, the inhaled insulin market faces concerns over the long-term safety and efficacy of using the pulmonary insulin delivery method. Occurrences of pulmonary fibrosis during clinical trials and the incidence of side effects are restraining the uptake of inhaled insulin.

In addition, due to high production costs, inhaled insulins are likely to be priced three to five times higher than conventional ones. This price premium will challenge manufacturers, although the price factor will be balanced out by its greater convenience.

"As the European markets are driven by the convenience factor, companies will need to analyse dosing accuracy, bioavailability and the device size," says Ms. Findlay. "This novel drug delivery method will have to demonstrate its advantages in terms of safety and accuracy relative to current insulin injections."

The ability to prove its safety and convenience will determine the uptake of the inhaled insulin method. Manufacturers of inhaled insulin devices will need to focus on the long-term safety and convenience aspects of their products, with the incorporation of newer techniques in inhaler devices set to enhance convenience.

Diabetes Drug Delivery Methods-Market and Technologies is part of the Pharmacueticals/Biotechology Subscription, which also includes research in the following markets: European Diabetes Market, European CNS Market Analysis, European Alzheimer's Market, European Cancer Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics and demographics. For more information, visit www.frost.com.

Diabetes Drug Delivery Methods-Market and Technologies
B934-52

 
For News Release background on Frost & Sullivan click here
 
Media Contact Details
Jasminder Kaur, Corporate Communications - Asia Pacific, Frost & Sullivan, +65 68900937, jkaur@frost.com
Melina Trevino, Corporate Communications - Americas, Frost & Sullivan, 210.247.2440, melina.trevino@frost.com
Radhika Menon Theodore, Corporate Communications - Europe, Frost & Sullivan, +91 (044) 4204 4541, rmtheodore@frost.com
Sharmin Jassal, Corporate Communications - Australia, Frost & Sullivan, + 61 2 8247 8900, sjassal@frost.com
 
KEYWORDS: Business/ Finance:Healthcare & biotechnology
 
Submit your press release
More News from Frost & Sullivan

15/10/2014 2:45PM Image

Maquet Medical India Pvt. Ltd. Wins “Operating Room Solutions Company of the Year” Award at Frost & Sullivan’s 6th Annual India Healthcare Excellence Awards 2014

Maquet Medical India Pvt. Ltd., has been awarded the ‘Operating Room Solutions Company of the Year’ for 2014 at Frost & Sullivan’s 6th Annual India Healthcare Excellence Awards.   Frost ...

01/10/2014 1:15PM

FORMCEPT Wins Frost & Sullivan’s 2014 New Product Innovation Leadership Award at GIL 2014: India

Frost & Sullivan bestowed the 2014 “Data Analysis Platforms” Award to FORMCEPT Technologies & Solutions (“FORMCEPT”) in the New Product Innovation Leadership category. The Award was ...

25/09/2014 4:30PM Image

Chairman Emeritus, Tata Sons, Mr. Ratan Tata Receives the Frost & Sullivan Growth, Innovation and Leadership Award for Visionary Innovation at GIL India: 2014

The sixth edition of GIL 2014: India concluded successfully at the Taj Lands End Hotel in Mumbai. Mr. Ratan Tata received the Frost & Sullivan Growth, Innovation and Leadership (GIL) Award for Visionary Innovation ...

Similar News

20/10/2014 5:54PM

Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of GED-0301 in 166 ...

No Image

20/10/2014 5:49PM

Killer Oestrogen: Lack of GSTM1 Responsible for Oestrogen Related Disorders

In a recent primary study, conducted by GeneSupport, Pune based nutri-genomics lab discovered substantial number of their clients who underwent nutrigenomics analysis for oestrogen, found to be lacking GSTM1 ...